Avita Medical Ltd. announced that it has signed distribution agreements for Japan and South Korea for its ReCell(r) device. In Japan, Avita will be represented by INDEE Medical, a new venture created by a group of experienced executives to specifically focus on the regenerative medicine sector, which has shown significant growth and interest since the November 2014 implementation of the Pharmaceutical and Medical Device Law, which has significantly cut the time it takes to gain marketing approval in Japan. INDEE Medical is assembling a team with a strong pedigree in the medical device sector and has a clear plan for managing ReCell(r) in its entry to the world's second large healthcare market by value.

In South Korea, Avita will be represented by TRM Korea, a Seoul-based company that for the past 25 years has distributed leading products focused on wounds, aesthetics and reconstructive surgery. South Korea has a burgeoning aesthetic sector, and one of the world's high per capita usages of plastic surgery. As such, Avita believes that South Korea will be fertile territory for the repigmentation and reconstructive benefits of the ReCell(r) device.

In Japan product registration will be through the Pharmaceutical and Medical Devices Agency (PMDA) and in South Korea by the Korean Food and Drug Administration (FDA).